Volume 10 Supplement 1
1033 Differences in dynamic changes in acute and chronic infarct size after bolus Gadolinium injection
© Palomares et al; licensee BioMed Central Ltd. 2008
Published: 22 October 2008
CMR is a highly accurate method of characterizing reversible and irreversible myocardial injury and obtaining information on residual myocardial viability for patient management and risk stratification. However, several studies suggested that in the acute and subacute setting, contrast hyperenhanced regions not only include infarcted myocardium, but also a portion of the area at risk (periinfarction zone), so that the overall extent of necrosis is overestimated. By contrast, studies in a canine model with 2-day-old reperfused infarcts showed that regions of hyperenhancement directly correspond to regions of infarcted tissue.
The aims of this study is to determine whether the time after Gd-DTPA injection over several minutes influences the size of contrast hyperenhancement in the setting of human reperfused acute and chronic MI, and determine the time after contrast injection that accurately predicts infarct size.
Subjects were evaluated using CMR within the first week (n = 60) and 3 months (n = 47) after a ST-segment elevation MI percutaneously revascularized. The inversion-recovery single-shot true fast imaging with steady-state precession (ss-IR) sequence was acquired 1, 3, 5, 7, 10, 15, 20, and 25 minutes after a bolus administration of 0.2 mmol/kg Gd-DTPA to analyze dynamic changes. Segmented inversion-recovery gradient-echo (seg-IR) sequences were acquired starting at 10 min after contrast and served as the gold standard for infarct size. Inversion time was properly adjusted at each time point to null normal myocardium. All images were blinded, randomized, and measured for hyper-enhancement volumes.
As previously shown in animals studies, we found that there is a change in infarct size over time in acute human reperfused MI not seen in the chronic phase. It is important to wait at least 10 minutes after contrast administration to ensure accurate determination of infarct size.
This article is published under license to BioMed Central Ltd.